


Accelerating Innovation: How CERN Technology Makes its Way into Society

Giovanni Anelli, Head of Knowledge Transfer Group, CERN

Four pillars underpin CERN's mission



Some historic examples







Our toolbox to accelerate innovation



Knowledge Transfer Channels

Dedicated actions to **foster the transfer of technologies and know-how** to other fields than particle physics (very often with the involvement of industry)

Technology-intensive procurement contracts

People

(very hard to quantify but extremely impactful for particle physics)



ACCELERATORS



Hybrid strategy: tech push & market pull

Mobilize tech experts

Create tech and IP dossiers

Scout for technologies

Mobilize innovation partners

Create value propositions

Search unmet needs











Shaping innovation partnerships

- Discussion with Innovation / R&D management
- Discovery day program at CERN
- Find mutual interest

Discover

Shape

- Define innovation ambitions and technical needs
- Discuss expertise contributed by partners
- Timeline, resources, IP

- Formalize partnership:
 - Collaborative R&D
 - License
 - Consultancy
 - Contract Research

Execute

Radioprotection 2005

DOI: 10.1051/radiopro:2005010

Vol. 40, n° 2, pages 245 à 255


Produit nouveau

Une nouvelle imagerie ostéo-articulaire basse dose en position debout : le système EOS

J. DUBOUSSET¹, G. CHARPAK², I. DORION², W. SKALLI³, F. LAVASTE³, J. DEGUISE⁴, G. KALIFA⁵, S. FEREY⁵



Georges Charpak, Fabio Sauli and Jean-Claude Santiard working on a multiwire chamber in 1970



From CERN technologies to medical and biomedical applications

Updated June 2023

https://cds.cern.ch/record/2864317/files/English.pdf

CERN/SPC/1091/RA CERN/FC/6125/RA CERN/3311/RA Original: English 23 May 2017

ORGANISATION EUROPEENNE POUR LA RECHERCHE NUCLEAIRE CERN EUROPEAN ORGANIZATION FOR NUCLEAR RESEARCH

Action to be taken

Voting Procedure

For information	SCIENTIFIC POLICY COMMITTEE 304th Meeting 12 & 13 June 2017	•
For information	FINANCE COMMITTEE 360th Meeting 13 & 14 June 2017	
For approval	RESTRICTED COUNCIL 185th Session 16 March 2017	Simple majority of Member States represented and votin

Strategy and framework applicable to knowledge transfer by CERN for the benefit of medical applications

The Council is invited to approve the strategy and framework set out in this document for medical applications-related activities, and to take note of the information contained in Annexes I and II.



ICT for medical applications

Nuclear Medicine

Medical Imaging

Radiotherapy


Radiation Monitoring and Dosimetry

Robotics

Medical devices



X-rays








https://link.springer.com/article/10.1186/1878-5085-4-9

Carbon ion beams



Relative dose



depth

EUROPEAN ORGANIZATION FOR NUCLEAR RESEARCH CERN - PS DIVISION

CERN/PS 2000-007 (DR)

PROTON-ION MEDICAL MACHINE STUDY (PIMMS) PART II

Accelerator Complex Study Group* supported by the Med-AUSTRON, Onkologie-2000 and the TERA Foundation and hosted by CERN

ABSTRACT

The Proton-Ion Medical Machine Study (PIMMS) group was formed following an agreement between the Med-AUSTRON (Austria) and the TERA Foundation (Italy) to combine their efforts in the design of a cancer therapy synchrotron capable of accelerating either light ions or protons. CERN agreed to support and host this study in its PS Division. A close collaboration was also set up with GSI (Germany). The study group was later joined by Onkologie-2000 (Czech Republic). Effort was first focused on the theoretical understanding of slow extraction and the techniques required to produce a smooth beam spill for the conformal treatment of complexshaped tumours with a sub-millimetre accuracy by active scanning with proton and carbon ion beams. Considerations for passive beam spreading were also included for protons. The study has been written in two parts. The more general and theoretical aspects are recorded in Part I and the specific technical design considerations are presented in the present volume, Part II. An accompanying CD-ROM contains supporting publications made by the team and data files for calculations. The PIMMS team started its work in January 1996 in the PS Division and continued for a period of four years.

*Full-time members: L. Badano 1 , M. Benedikt 2 , P.J. Bryant 2 (Study Leader), M. Crescenti 1 , P. Holy 3 , A. Maier $^{2)+0}$, M. Pullia 1 , S. Reimoser $^{2)+0}$, S. Rossi 1 ,

Part-time members: G. Borri¹⁾, P. Knaus¹⁾⁺²⁾

Contributors: F. Gramatica11, M. Pavlovic41, L. Weisser51

- 1) TERA Foundation, via Puccini. 11, I-28100 Novara.
- 2) CERN, CH 1211 Geneva-23.
- 3) Oncology-2000 Foundation, Na Morani 4, CZ-12808 Prague 2.
- 4) Med-AUSTRON, c/o RIZ, Prof. Dr. Stephan Korenstr.10, A-2700 Wr. Neustadt.
- 5) Sommer & Partner Architects Berlin (SPB), Hardenbergplatz 2, D-10623 Berlin.


Geneva, Switzerland May 2000

PIMMS August 2000

From the PIMMS Study @







Hadron therapy

Active since the 1990s:

- synchrotrons for C-ion therapy
- linear accelerators for innovative proton therapy systems




Licensed to AVO (Advanced Oncotherapy) – ADAM

Since 2019:

focus on innovative technologies for multi-ion therapy







1680 patients treated 2017-2022

EUROPEAN ORGANIZATION FOR NUCLEAR RESEARCH CERN - PS DIVISION

CERN/PS 2000-007 (DR)

PROTON-ION MEDICAL MACHINE STUDY (PIMMS) PART II


Accelerator Complex Study Group* supported by the Med-AUSTRON, Onkologie-2000 and the TERA Foundation and hosted by CERN



FLASH VHEE therapy

CLIC technology for a FLASH VHEE facility being developed in collaboration with CHUV (Lausanne University Hospital) and THERYQ (ALCEN Group)





An intense beam of electrons is produced in a photoinjector, accelerated to around 100 MeV and then is expanded, shaped and guided to the patient.

The design of this facility is the result of an intense dialogue between groups at CHUV and CERN.

Jean Bourhis from CHUV:

"The clinical need that we have really converges with the technological answer that CERN has."

The remarkable connection between CLIC technology and FLASH electron therapy



Very intense electron beams

CLIC – to provide brightness needed for delicate physics experiments

FLASH – to provide dose fast for biological FLASH effect

Very precisely controlled electron beams

CLIC – to reduce the power consumption of the facility FLASH – to provide reliable treatment in a clinical setting

High accelerating gradient (that is high beam energy gain per length)

CLIC – fit facility in Lac Leman region and limit cost FLASH – fit facility on typical hospital campuses and limit cost of treatment



FLASH therapy – a growing clinical interest



Vozenin et al Clin Cancer Res 2018



Contents lists available at ScienceDirect

Radiotherapy and Oncology

journal homepage: www.thegreenjournal.com



Original Article

Treatment of a first patient with FLASH-radiotherapy

Jean Bourhis ^{a,b,*}, Wendy Jeanneret Sozzi ^a, Patrik Gonçalves Jorge ^{a,b,c}, Olivier Gaide ^d, Claude Bailat ^c, Fréderic Duclos ^a, David Patin ^a, Mahmut Ozsahin ^a, François Bochud ^c, Jean-François Germond ^c, Raphaël Moeckli ^{c,1}, Marie-Catherine Vozenin ^{a,b,1}

*Department of Radiation Oncology, Lausanne University Hospital and University of Lausanne; bRadiation Oncology Laboratory, Department of Radiation Oncology, Lausanne University Hospital and University of Lausanne; bistitute of Radiation Physics, Lausanne University Hospital and University of Lausanne; and Department of Dermatology, Lausanne University Hospital and University of Lausanne. Switzerland




Fig. 1. Temporal evolution of the treated lesion: (a) before treatment; the limits of th PTV are delineated in black; (b) at 3 weeks, at the peak of skin reactions (grade 1 epithelitis NCI-CTCAE v 5.0); (c) at 5 months.


First human patient – skin cancer treated with 10 MeV-range electrons

Medipix

A family of pixel detector read-out chips for particle imaging and detection developed by the Medipix Collaborations










Spectroscopic information permits material separation






The water has been partly cut away to reveal the bone, gold, gadolinium and iodine


Images presented and the European Congress of Radiology, Vienna, March 2017.




Colour x-ray of a lighter










S. Procz et al.



MiniPIX TPX3

Miniaturized spectral camera supporting Si and CdTe sensors




It's really small...










CERN-MEDICIS



Non-conventional isotopes collected by mass separation for new medical applications




MEDICIS Target
Irradiation

"Free" proton beam (otherwise lost in the dump)

Rail Conveyor System





68Ga-PSMA-11 PET/CT scans of patient B. In comparison to initial tumor spread (A), restaging after 2 cycles of β-emitting 177Lu-PSMA-617 presented progression (B).

Clemens Kratochwil et al. J Nucl Med 2016;57:1941-1944





NATURE | NEWS FEATURE



Radioisotopes: The medical testing crisis

With a serious shortage of medical isotopes looming, innovative companies are exploring ways to make them without nuclear reactors.

Richard Van Noorden


11 December 2013





Radioisotopes & Nuclear Medicine

Classification of isotopes for Medicine:





Courtesy U. Koester

Theranostics

Tb 149		
4.2 m	4.1 h	
E	€ /	
β+	a 3.97	
α 3.99	β+1.8	
γ 796;	y 352;	
165	165	

Tb 152		
4.2 m	17.5 h	
ly 283;	6	
160	β+ 2.8	
ε; β*	y 344;	
y 344;	586;	
411	271	

Tb 155 5.32 d ε γ 87; 105;... 180, 262 Tb 161 6.90 d β-0.5; 0.6... γ 26; 49; 75... e



A Unique Matched Quadruplet of Terbium Radioisotopes for PET and SPECT and for α - and β -Radionuclide Therapy: An In Vivo Proof-of-Concept Study with a New Receptor-Targeted Folate Derivative

Cristina Müller, Konstantin Zhernosekov, Ulli Köster, Karl Johnston, Holger Dorrer, Alexander Hohn, Nico T. van der Walt, Andreas Türler and Roger Schibli Journal of Nuclear Medicine December 2012, 53 (12) 1951-1959; DOI: https://doi.org/10.2967/jnumed.112.107540



CAFEIN

A modular **federated learning** platform to support medical analysis, diagnosis and predictions.

Reing applied to brain imaging, cancer screening.

Being applied to brain imaging, cancer screening, stroke management.

EC-funded project Trustroke.



CAIMIRA

a risk assessment tool developed to model the **concentration of viruses in enclosed spaces**

Collaboration with WHO.

Open-source, used worldwide

MARCHESE

Remote contactless human recognition and health monitoring system. Neonatal monitoring, rehab, elderly patients, search and rescue.

Collaboration with CHU Lille.

```
#selection at the end -add back the deselected mirror modifier object
mirror_ob.select= 1
modifier_ob.select=1
bpy.context.scene.objects.active = modifier_ob
print("Selected" + str(modifier_ob)) # modifier ob is the active ob
mirror_ob.select = 0
```

BioDynaMo

An agent-based simulation environment for multidisciplinary use

Open source, collaboration for specific use cases















License



MARS Bio Imaging: next generation X ray finally in color using CERN chips





Key lessons learned

- CERN is strong in the 'extremes' of the technology scale
- You need passionate experts on both sides to succeed
- Start with a concrete project and clear business need
- Mind the gap in language, 'clockspeed' and culture
- Driving deep tech innovation requires courage

Key challenges

- CERN experts are busy
- Our technologies have low TRL
- What is our Unique Value Proposition?

Molte grazie per l'attenzione